Bladder Cancer Clinical Trials in Shanghai, Shanghai Municipality
12 recruitingShanghai, Shanghai Municipality, China
Showing 1–12 of 12 trials
Recruiting
Phase 2
Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled15 locationsNCT07283835
Recruiting
Phase 2
Tremelimumab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
Bladder Cancer
Changhai Hospital31 enrolled1 locationNCT07307456
Recruiting
Phase 2
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705
Recruiting
Phase 2
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
Bladder CancerNeuroendocrine Carcinoma of the Bladder
RenJi Hospital22 enrolled5 locationsNCT06091124
Recruiting
Not Applicable
Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy
Bladder Cancer
Changhai Hospital180 enrolled1 locationNCT07204132
Recruiting
A Cell-free DNA Methylation Blood-Based Test for Biliary Tract Cancers Screening
ctDNAGall Bladder CancerIntrahepatic Cholangiocarcinoma (Icc)+3 more
Yingbin Liu, MD, PhD, FACS1,800 enrolled1 locationNCT07176962
Recruiting
Phase 4
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
SurgeryBladder CancerCancer Recurrence+2 more
Peking University First Hospital1,128 enrolled6 locationsNCT04532606
Recruiting
Phase 2Phase 3
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Muscular Invasive Bladder Cancer (MIBC)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.840 enrolled1 locationNCT06879145
Recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
Non-Muscle-Invasive Bladder Cancer (NMIBC)
Jiangsu Simcere Pharmaceutical Co., Ltd.152 enrolled14 locationsNCT06186414
Recruiting
Phase 1Phase 2
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
Bladder CancerNon Muscle Invasive
Zhuhai Beihai Biotech Co., Ltd48 enrolled6 locationsNCT06732531
Recruiting
Phase 1
A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.170 enrolled1 locationNCT06108492
Recruiting
Phase 2
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
HER2Non Muscle Invasive Bladder Cancer
RenJi Hospital20 enrolled1 locationNCT05957757